Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P556: Cyclosporine in acute severe steroid-refractory ulcerative colitis: Short-and long-term outcomesECCO '18 Vienna
Year: 2018
Authors:

A. Hammami*, B. Hasnaoui, S. Hachicha, M. Ksiaa, H. Jaziri, N. Elleuch, A. Brahem, S. Ajmi, A. Ben Slama, A. Jmaa

Hospital University of Sahloul, Gastroenterology, Sousse, Tunisia

P557: Cost-effectiveness of infliximab vs. surgery for severe chronic ulcerative colitis: a Markov analysisECCO '18 Vienna
Year: 2018
Authors:

S. Holubar1*, P. Dulai2, B. Piazik3, S. Finlayson4, B. Udeh5

1Cleveland Clinic, Department of Colon and Rectal Surgery, Cleveland, USA, 2University of California San Diego, Medicine, San Diego, USA, 3Elliot Health Systems, Manchester, USA, 4University of Utah, Surgery, Salt Lake City, USA, 5Cleveland Clinic, Clinical Transformation, Cleveland, USA

P558: Golimumab improves patient-reported work productivity and activity impairment in patients with ulcerative colitis: Interim results from a non-interventional trial in GermanyECCO '18 Vienna
Year: 2018
Authors:

N. Teich1, H. Grümmer2, E. Jörgensen3, T. Liceni4, F. Holtkamp-Endemann5, F. Cornillie6, S. Hohenberger7, T. Fischer7*

1Internistische Gemeinschaftspraxis für Verdauungs- und Stoffwechselkrankheiten Leipzig und Schkeuditz, Leipzig, Germany, 2Praxis Grümmer, Potsdam, Germany, 3Magen Darm Zentrum Remscheid, Remscheid, Germany, 4MVZ für Gastroenterologie am Bayerischen Platz, Berlin, Germany, 5Gastroenterologische Gemeinschaftspraxis am Germania-Campus, Münster, Germany, 6MSD, Global Medical Affairs, Luzern, Switzerland, 7MSD, Medical Affairs, Haar, Germany

P559: Tacrolimus as a topical therapy for perianal Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

B. Nanaeva1*, M. Shapina2, I. Khalif1

1Federal State Establishment State Scientific Centre of Coloproctology, Department of Inflammatory and Functional Bowel Diseases Study, Moscow, Russian Federation, 2Federal State Budgetary Institute State Scientific Center of Coloproctology of Russian Ministry of Health, Gastroenterology, Moscow, Russian Federation

P560: Granulocyte–monocyte apheresis combination therapy after loss of response to anti-TNF drugsECCO '18 Vienna
Year: 2018
Authors:

I. Rodríguez-Lago1*, L. Sempere2, A. Gutiérrez2,3, B. Beltrán4, E. Saez4, E. Hinojosa5, M. Mora5, F. Cañete6, M. Mañosa6, S. Khorrami7, D. Ginard7, J.L. Cabriada1

1Hospital de Galdakao, Gastroenterology, Galdakao, Spain, 2Hospital General Universitario de Alicante, Gastroenterology, Alicante, Spain, 3CIBEREHD (Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas), Alicante, Spain, 4Hospital De La Fe, Gastroenterology, Valencia, Spain, 5Hospital de Manises, Gastroenterology, Manises, Spain, 6Hospital Universitari Germans Trias I Pujol, Gastroenterology, Badalona, Spain, 7Hospital Son Espases, Gastroenterology, Palma de Mallorca, Spain

P561: A comparison of medication adherence and persistence between intravenous biologics and oral small-molecule therapiesECCO '18 Vienna
Year: 2018
Authors:

S. Kane1, K. Moran2, K. Null2, Z. Huang2, T. Lissoos2*

1Mayo Clinic, Rochester, USA, 2Takeda Pharmaceuticals USA, Inc., Deerfield, USA

P562: Role, efficacy and safety of budesonide multi-matrix in ulcerative colitis in real life: A study in three Italian third-level centresECCO '18 Vienna
Year: 2018
Authors:

S. Landi1*, N. Mezzina2, S. Carmagnola2, M. Bosani3, E. Filippi4, L. Pastorelli4, S. Grillo1, A. Massari2, A. Cassinotti2, P. Moulteni2, A. Dell'Era2, S. Ardizzone2, G. Maconi2

1Gastroenterology Unit, University of Parma, Parma, Italy, 2Gastrointestinal Unit, ASST Fatebenefratelli Sacco, DIBIC “L. Sacco” University of Milan, Milan, Italy, 3Gastroenterology and Endoscopic Unit, Legnano Hospital, Legnano, Italy, 4I.R.C.C.S. Policlinico San Donato Gastroenterology and Digestive Endoscopy Unit, San Donato Milanese (Milan), Italy

P563: Stopping anti-TNFα monotherapy in Crohn's disease patients in deep remission and favourable disease characteristics is associated with a high rate of relapseECCO '18 Vienna
Year: 2018
Authors:

K. Soufleris1*, N. Kafalis1, K. Fasoulas1, G. Lazaraki1, I. Pilpilidis1, D. Tzilves1, O. Giouleme2

1Theagenion Cancer Hospital of Thessaloniki, Gastroenterology Department, Thessaloniki, Greece, 2Hippokration General Hospital of Thessaloniki, Second Propedeutic Department of Internal Medicine, Thessaloniki, Greece

P564: Indigo naturalis induces mucosal healing in patients with ulcerative colitis: A multicentre randomised controlled trialECCO '18 Vienna
Year: 2018
Authors:

M. Naganuma1*, S. Sugimoto1, K. Mitsuyama2, T. Kobayashi3, N. Yoshimura4, H. Ohi5, K. Matsuoka6, T. Hisamatsu7, K. Watanabe8, T. Abe9, M. Watanabe6, T. Hibi3, Y. Suzuki10, T. Kanai1, INDIGO study group

1Keio University, Division of Gastroenterology and Hematology, Tokyo, Japan, 2Kurume University School of Medicine, Division of Gastroenterology, Department of Medicine, Kurume, Japan, 3Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan, 4Tokyo Yamate Medical Center, Department of Internal Medicine, Division of IBD, Tokyo, Japan, 5Imamura Hospital, Department of Gastroenterology, Kagoshima, Japan, 6Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan, 7Kyorin University School of Medicine, The Third Department of Internal Medicine, Mitaka, Japan, 8Hyogo College of Medicine, Department of Intestinal Inflammation Research, Nishinomiya, Japan, 9Keio University School of Medicine, Medicine and Public Health, Biostatistics Unit at Clinical and Translational Research Center, Tokyo, Japan, 10Toho University Sakura Medical Center, Department of Internal Medicine, Division of IBD, Sakura, Japan

P565: Real-world use of azathioprine metabolites changes clinical management of inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

S. Tuson1, L. Wilson1, L. Yang2,3, D. Loomes1,3*

1Vancouver Island IBD Clinic, Victoria, Canada, 2Island Health, Department of Laboratory Medicine, Pathology and Medical Genetics, Victoria, Canada, 3University of British Columbia, Faculty of Medicine, Vancouver, Canada

P566: Effect of polyethylene glycol (PEG) bowel preparation on faecal calprotectin levels in patients with ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

C. Herrera-deGuise*, E. Varela, V. Robles, F. Casellas, N. Borruel

Hospital Universitari Vall d'Hebron, Digestive Disease Research Unit, Barcelona, Spain

P567: Long-term outcome of perianal fistulae treated with anti-TNFα therapy in a cohort of Saudi patients with Crohn’s disease based on Parks classificationECCO '18 Vienna
Year: 2018
Authors:

N. Azzam1*, O. Alharbi1, A. Aljebreen1, A. Mohammed1, S. Bahammam1, A. Bashmail1, Y. Alomar1, M. Mosli2, M. Almadi1

1King Saud University, Medicine, Riyadh, Saudi Arabia, 2King Abdul-Aziz University, Medicine, Jeddah, Saudi Arabia

P568: The impact of a virtual clinic on clinical decision-making and healthcare resource use vs. standard care: The Oxford experienceECCO '18 Vienna
Year: 2018
Authors:

M. FitzPatrick*, T. Ambrose, L. Thomas, S. Cullen, G. Blackburn, K. Davies, S. Travis, S. Keshav, A. Walsh, R. Palmer, S. Cripps, O. Brain

Translational Gastroenterology Unit, Oxford, UK

P569: Outcomes of IBD patients treated with infliximab: The impact of therapeutic drug monitoring in real-life clinical practiceECCO '18 Vienna
Year: 2018
Authors:

N. Kamperidis, P. Middleton, T. Tyrrell, I. Stasinos, N. Arebi

St Mark's Hospital, London, UK

P570: Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: Results from GEMINI trial dataECCO '18 Vienna
Year: 2018
Authors:

D.T. Rubin1, D. Tudor2, J.M. Khalid3, H. Patel3*

1University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA, 2Takeda Pharmaceuticals International AG, Zurich, Switzerland, 3Takeda Development Centre Europe Ltd., Evidence and Value Generation, London, UK

P571: Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)ECCO '18 Vienna
Year: 2018
Authors:

S.S.R. Pulusu1*, A. Srinivasan2, K. Krishnaprasad3, D. Cheng4, T. Mogilevski5, E. Flanagan6, C. Keung7, C. Wu8, R. Prosser9, E. Sawyer10, Q.-U.-A. Rizvi11, H. Su12, W.-K. Leung13, A. Edmundson3, S. Cooke14, G. Mahy14, L. Thin15, G. Radford-Smith16, M. Sparrow12, J.M. Andrews11, S. Connor10, P. Bampton17, S. Ghaly8, D. Van Langenberg7, S. Bell6, P. De Cruz5, J. Begun4, S. Ng18, S. Travis2, I. Lawrance1

1St John of God, Subiaco, IBD Center, Perth, Australia, 2Oxford University Hospitals, Oxford, UK, 3QIMR Berghofer Medical Research Institute, Brisbane, Australia, 4Mater Hospital, Brisbane, Australia, 5Austin Health, Melbourne, Australia, 6St Vincents Hospital, Melbourne, Australia, 7Eastern Health, Melbourne, Australia, 8St Vincents Hospital, Sydney, Australia, 9Flinders Medical centre, Adelaide, Australia, 10Liverpool Hospital, Sydney, Australia, 11Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia, 12The Alfred Hospital, Melbourne, Australia, 13The Chinese University of Hong Kong, Hong Kong, Hong Kong, 14Townsville Hospital, Townsville, Australia, 15Fiona Stanley Hospital, Perth, Australia, 16QIMR Berghofer Medical Research Institute, Brisbane, Australia, 17Flinders Medical Centre, Adelaide, Australia, 18The Chinese University of Hong Kong, Honk kong, Hong Kong

P572: Reactive dose escalation of infliximab in patients with Crohn’s disease in TAILORIX leads to improved outcomesECCO '18 Vienna
Year: 2018
Authors:

E. Dreesen1*, D. Laharie2, G. Lambrecht3, P. Bossuyt4, A. Buisson5, J. Filippi6, P. Van Hootegem7, G. D'Haens8, S. Vermeire9,10, A. Gils1

1KU Leuven, Departement of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 2Hospital Haut-Lévêque, Bordeaux, France, 3Damiaan Hospital, Oostende, Belgium, 4Imelda Hospital, Bonheiden, Belgium, 5Hospital Estaing, Clermont-Ferrand, France, 6Hospital Archet, Nice, France, 7Sint-Lucas Hospital, Brugge, Belgium, 8Academic Medical Centre, Amsterdam, The Netherlands, 9University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 10KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium

P573: Safety and immune modulatory properties of etrasimod (APD334), a next-generation oral, selective sphingosine 1-phosphate receptor (S1PR) modulator, in healthy volunteersECCO '18 Vienna
Year: 2018
Authors:

L. Peyrin-Biroulet1, J. Adams2, S. Turner2, L. Trokan2, J. Panes3*

1Lorraine University, Department of Gastroenterology and Inserm U954, Nancy, France, 2Arena Pharmaceuticals, Inc., San Diego, USA, 3Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

P574: The effects of vagus nerve stimulation in biologic-refractory Crohn’s disease: A prospective clinical trialECCO '18 Vienna
Year: 2018
Authors:

G. D'Haens1*, Z. Cabrijan2, M. Eberhardson3, R. van den Bergh1, M. Löwenberg1, G. Fiorino4, S. Danese4, Y. Levine5, D. Chernoff5

1Academic Medical Center (AMC) University of Amsterdam, Amsterdam, The Netherlands, 2School of Medicine, University of Osijek, Osijek, Croatia, 3Karolinska Institute, Stockholm, Sweden, 4Humanitas Clinical Institute, Milan, Italy, 5SetPoint Medical, Inc., Valencia, USA

P575: Vedolizumab trough levels predict clinical outcomes in inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

L. Guidi1*, D. Pugliese1, T. Panici Tonucci1, B. Tolusso2, C. Felice1, C. Di Mario2, A. Papa1, E. Gremese2, A. Gasbarrini3, G.L. Rapaccini1, A. Armuzzi1

1Fondazione Policlinico A. Gemelli, Catholic University, Internal Medicine and Gastroenterology Unit, Presidio Columbus, Rome, Italy, 2Fondazione Policlinico A. Gemelli, Catholic University, Rheumatology Unit, Presidio Columbus, Rome, Italy, 3Fondazione Policlinico A. Gemelli, Catholic University, Internal Medicine and Gastroenterology Unit, Rome, Italy